Abuse of Superior Bargaining Position (ASBP) guidelines, 173–174
aggregation, of patents under antitrust law, 25
Cournot complements problem, 20–21
intellectual property and, 2
mass aggregators, 4
PAEs as, 2
by patent trolls, 18–21
by PEs, 18–21
technological costs of, 20
transaction cost reduction through, 20

Allison, Lemley & Walker (ALW) taxonomy, 55

Antimonopoly Act (Japan), 164–166
ASBP guidelines, 173–174
competition requirements under, 166–167
excessive pricing and, 173–174
exemptions under, 164–166
private monopolization restrictions, 167–168
refusal of license under, 167–171
unfair trade practices under, 167–168

Anti-Monopoly Law (AML) (China), 154, 159–160
antitrust law. See also patent litigation
aggregation of patents under, 25
in Asian region, 77–78
in Europe, 77–78
FRAND royalties under, 81–82
hybrid PAEs and, 73–74
IP law and, 130
in Korea, 132–133
patent privatizing and, 80
in U.S., 77–78

Anti-Unfair Competition Law (China), 157–159
Apple v. Samsung, 142–144

ASBP guidelines. See Abuse of Superior Bargaining Position guidelines
Asia. See also China; Japan; Korea; Taiwan
antitrust law in, 78–82
FRAND royalties in, 78–83
bartering, PEs and, 12
bottom-feeder patent trolls, 11, 21–22, 25, 85
demand letters by, 86
MPJH Technology, 87–88, 93–94
under patent law, 87–88
cash-targeting strategies, 39–40
Chien, Colleen, 107, 182
China
AML in, 154, 159–160
hybrid PAE claims in, 78–82
FRAND royalty commitments, 78–79
MOFCOM and, 78–79, 150–152
Nokia in, 150–152
PAEs in, 150–154, 160–161
under AML, 159–160
under Anti-Unfair Competition Law,
157–159
formal adoption of, 152–153
government regulation of, 150–152
improper conduct of, 155–160
as insignificant legal problem, 154–155
international cases, 150
legal regulation of, 153–160
MOFCOM and, 150–152
negative functions of, 153–154
Patent Law of, 150
patent trolls in, 152–153
Clayton Act (U.S.), 75–76
Commonwealth Scientific and Industrial Research Organisation (CSIRO), 52
competition law, in Japan, 164–166
Constitution, U.S.
under First Amendment, 92, 94–95
Supremacy Clause, 92
contract law, FRAND royalty commitments and, 80–81
Cournot complements problem, 20–21
cross-licensing, of patents, 13
CSIRO. See Commonwealth Scientific and Industrial Research Organisation
damage awards
assessment of, for PEs, 14–16
for patent litigation
in Europe, 123
in U.S., 114
demand letters, 33
by bottom-feeder patent trolls, 86
under Korean IPR guidelines, 146
under patent law, 86
at federal level, 90–91
at state level, 88–90
under TROL Act, 91, 99–101
England. See United Kingdom
Europe. See also Germany; United Kingdom
antitrust law in, 77–78
hybrid PAE claims in, 77–78
PEs in, 106–107
patent litigation and, 108–109
PAEs in, 104, 107–114
lack of activity for, 115–124
patent litigation in, 105–106
costs of, 123
damage awards for, 123
fee-shifting in, 123
by NPE type, 108–109
for software-based patents, 115–116
unitary patent system in, 117, 124
European Patent Convention, 115–116
ex post licensing, for NPEs, 29
“fair, reasonable and non-discriminatory” (FRAND) royalties
under antitrust law, 81–82
contract law and, 80–81
in hybrid PAE claims, 79
in China, 78–79
in Korea, 141–142
PAEs and, 193–195
hybrid, 78–79
in Korea, 141–142
SEPs and, 50, 54
property law and, 80–81
SEPs and, 50, 54
for SSOs, 50, 54, 194
Farris v. Glen Allen Corporation, 82
Federal Trade Commission (FTC), 90–91
fee-shifting, in patent litigation, 123
First Amendment, immunity doctrine under, 92, 94–95
forum shopping, for NPE litigation, 36–38
FRAND royalties. See “fair, reasonable and non-discriminatory” royalties
FTC. See Federal Trade Commission
Germany
PEs in, 107–110
patent litigation in, 105–106, 119–122
case settlement rates, 114
by case type, 112
case value of, 114
costs of, 116–117
damage awards for, 117–118
injunctions in, 118
invalidation of patents and, 118
IPCs and, 110
non-monetary remedies and, 118
PAEs and, 110–112
U.S. standards for, 114
win rates for, 110, 114
GSK/Dong-A Reverse Payment case, 136–139
Holmes v. Lerner, 81–82
Hovenkamp, Areeda, 75
hybrid PAEs, 6
antitrust law and, 73–74
in Asian region, 78–83
in China, claims for, 78–82
FRAND royalty commitments, 78–79
MOFCOM, 78–79
under Clayton Act, 75–76
in Europe, 77–78
FRAND royalties, 78–79
incentives of, 73–77
in Korea, 79
PEs and, 73
RRC strategy and, 75
SSOs and, 81

in Taiwan, claims for, 78–82
in U.S., 77–78, 82–83
immunity doctrine, for regulation of patent assertions, 86, 92–96
Federal Circuit Court development of, 92–94, 99
under First Amendment, 92, 94–95
as matter of preemption, 92
MPJH and, 93–94
re-assessment of, 94–97
under Supremacy Clause, 92
information technology (IT) industry
patent trolls and, 9, 24
PEs and, 16–18
injunctions
in German patent litigation cases, 118
against patent trolls, 24
for PEs, 15
in U.S. patent litigation cases, 118
Innovatio IP Ventures, 51, 87–88
innovation
NPE patent litigation as influence on, 31–32, 42–43
PAEs and, 5
intellectual property (IP)
anti-trust law and, 150
JFTC guidelines, 170–171
in Korea, guidelines for, 131–147
deceptive demand letters, 146
FRAND royalty terms, 140–142
imposition of unreasonable royalties, 140–141
KFTC amending of, 139
PAEs under, 131–133, 140–147
third-party patents and, 141–142
PAEs as aggregation of, 2
privateering, 154–185
Intellectual Property and Enterprise Court (IPEC), 105–106
Intellectual Property Basic Act (Japan), 163
International Patents Classifications (IPCs), 110
invalidation of patents, 118
inventors, NPEs patent litigation and, 44–46
IP. See intellectual property
IPCs. See International Patents Classifications
IPEC. See Intellectual Property and Enterprise Court
IT industry. See information technology
industry
Japan
Antimonopoly Act, 164–166
ASBP guidelines, 173–174
competition requirements under, 166–167
excessive pricing and, 173–174
exemptions to, 164–166
private monopolization restrictions, 167–168
refusal of license under, 167–171
unfair trade practices under, 167–168
Civil Procedure Code in, 162
competition law in, 164–166
PAEs in, 162
competition requirements for, 166–167
excessive pricing restrictions, 173–174
under Intellectual Property Basic Act, 163
legal foundations for, 162–163
mergers restrictions for, 174
under Patent Act, 164–166
refusal of license provisions, 167–171
patent law in, 164–166
UCPA, 163
false announcement provisions, 171–173
Innovation v. One Blue, 172–173
Japan Fair Trade Commission (JFTC), 167–171
IP guidelines, 170–171
Pachinko case, 168–169
Roppo v. Hinode, 169
KFTC. See Korea Free Trade Commission
Korea
Apple v. Samsung in, 142–144
hybrid PEs claims in, 79
IPR in, guidelines for, 131–147
deceptive demand letters, 146
FRAND royalty terms, 140–142
imposition of unreasonable royalties, 140–141
KFTC amending of, 139
PAEs under, 131–133, 140–147
third-party patents and, 141–142
MRFTA and, 133–139
abuse of market dominant position, 134–136
Article 59, 136
GSK/Dong-A Reverse Payment case, 136–139
unfair collaborative acts under, 134
PAEs in, 131, 148
under anti-trust law, 132–133
formation of consortiums among, 145
Korea (cont.)
FRAND royalty terms, 141–142
imposition of unreasonable royalties, 140–141
under IPR guidelines, 131–133, 140–147
patent litigation, 131
patent privateering and, 146–147
third-party patents and, 142–144
patent litigation systems in, 147
Qualcomm case in, 144–145
SEPs in, 141–142
Korea Free Trade Commission (KFTC), 131–133. See also Monopoly Regulation and Fair Trade Act
IPR guidelines amended by, 139
lawsuits, PAEs and, 1, 5
legal activity. See antitrust law; injunctions; lawsuits
licensing, of patents
cross-licensing, 15
ex post, for NPEs, 29
in Japan, refusal of license provisions, 167–171
PAEs and, 2, 186
strategies for, 29
“lottery ticket trolls.” 4. See also patent assertion entities
MAD. See mutually assured destruction
mass aggregators, 4
McMillan, Robert, 76
mergers
in Japan, for PAEs, 174
patent privateering and, 75–76
antitrust law and, 80
defined, 72
functions of, 72
Microsoft, as hybrid PAE, 77–82
Ministry of Commerce of the People’s Republic of China (MOFCOM), 78–79, 150–152
Monopoly Regulation and Fair Trade Act (MRFTA) (Korea), 133–139
abuse of market dominant position, 134–136
exclusionary abuse, 134–135
exploitative abuse, 135
unfair trade practices as, 135–136
Article 59, 136
GSK/Dong-A Reverse Payment case, 136–139
unfair collaborative acts under, 134
MOSAID, 76–77
MPJH Technology, 87–88, 93–94
MRFTA. See Monopoly Regulation and Fair Trade Act
mutually assured destruction (MAD), of patent firms
defined, 73
PAEs and, 3
N-Data, 31
Nokia
in China, 150–152
as hybrid PAE, 77–82
Nokia v. TFTC, 178–185
classification of legal issues in, 181–182
decision appeals, 180–181
privateering PAEs and, 184–185
problems with decision, 186–187
TFTC decision, 179–180
non-monetary remedies, in patent litigation, 118
non-practicing entities (NPEs). See also patent assertion entities
classification system for, 55
ALW taxonomy, 55
defined, 106–107
demand letters, 33
in Europe, 106–107
patent litigation by type, 108–109
ex post licensing for, 29
hybrid PAEs and, 73
licensing strategies, 29
PAEs compared to, 130–131
under patent law and regulation, 87–88
patent litigation and, 27–28
aggregate trends, 32–34
cash-targeting strategies in, 39–40
costs to targeted firms, 43–44
cross-country evidence for, 33–34
in Europe, 108–109
forum shopping for, 36–38
innovation reduction as result of, 31–32,
42–43
large sample evidence for, 31–41
patent quality as factor in, 32, 34–41
PE litigation compared to, 39–41
plaintiff classification and, 32–33
survey evidence for, 29–31
transfers to inventors and, 44–46
pro-competitive aspects of, 2

© in this web service Cambridge University Press

www.cambridge.org
Index

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>203</td>
</tr>
</tbody>
</table>

publicly-traded, 45
SEPs and
limitations of, 63–64
litigation outcomes, 61–62, 68, 71
long-term implications of, 64–65
methodology for, 52–55
plaintiff characteristics, 58–61, 69–70
study design for, 52–55, 65–64
types of, 106
non-standard setting organizations (non-SSOs), 81
NPEs. See non-practicing entities
PACS. See picture archival and communications systems
PAEs. See patent assertion entities
PATENT Act. See Protecting American Talent and Entrepreneurship Act
Patent Act (Japan), 164–166
patent assertion entities (PAEs). See also non-practicing entities
anti-competitive aspects of, 3, 74–75
in China, 150–154, 160–161
under AML, 159–160
under Anti-Unfair Competition Law, 157–159
formal adoption of, 152–153
government regulation of, 150–152
improper conduct of, 155–160
as insignificant legal problem, 154–155
international cases for, 150
legal regulation of, 153–160
MOFCOM and, 150–152
negative functions of, 153–154
CSIRO, 52
defined, 107, 182–184
in Europe, 104, 107–124
lack of activity for, 115–124
FRAND royalties, 103–105
for hybrid PAEs, 75–79
in Korea, 141–142
SEPs and, 50, 54
hybrid, 6
antitrust law and, 73–74
in Asian region, 78–83
in China, 78–82
under Clayton Act, 75–76
in Europe, 77–78
FRAND royalties, 78–79
incentives of, 73–77
in Korea, 79
NPEs and, 73
RRC strategy and, 75
SSOs and, 81
in Taiwan, 78–82
in U.S., 77–78, 82–83
increased activity for, 1
Innovatio, 51
intellectual property and, aggregation of, 2
in Japan, 162
competition requirements for, 166–167
excessive pricing and, 173–174
excessive pricing restrictions, 173–174
under Intellectual Property Basic Act, 165
legal foundations for, 162–165
mergers restrictions for, 174
under Patent Act, 164–166
refusal of license provisions, 167–171
in Korea, 131, 148
under antitrust law, 132–133
formation of consortia and, 145
FRAND royalty terms, 144–142
imposition of unreasonable royalties, 140–141
under IPR guidelines, 133–135, 140–147
KFTC and, 131–132
MRFTA and, 133
patent litigation, 131
patent privateering and, 146–147
third-party patents and, 141–142
lawsuits and, 1, 5
licensing of patents, 2, 186
litigation strategies, 186
MAD and, 3
Microsoft, 77–78
N-Data, 51
Nokia, 77–78
NPEs compared to, 130–131
patent litigation and, 27. See also Nokia v. TFTC
predatory pricing models and, 2
price-fixing and, 189
privateering, 184–185
qualitative approach to, 188–193
disaggregators in, 189–190
economic rationality in, 191–193
government agencies and, 190–191
industry stakeholders in, 190–191
SEPs in, 192–193
quantitative approach, 187–188
Rembrandt, 52
<table>
<thead>
<tr>
<th>patent assertion entities (PAEs). (cont.)</th>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>rent seeking and, 5</td>
<td>Apple v. Samsung, 142–144</td>
</tr>
<tr>
<td>risk asymmetry of, 3</td>
<td>damage awards for</td>
</tr>
<tr>
<td>Rockstar, 51</td>
<td>in Europe, 123</td>
</tr>
<tr>
<td>RRC theory and, 177, 183</td>
<td>in U.S., 114</td>
</tr>
<tr>
<td>SEPs and, 50–51</td>
<td>in Europe, 105–106</td>
</tr>
<tr>
<td>assertion landscape, 56–58</td>
<td>costs of, 123</td>
</tr>
<tr>
<td>FRAND royalties, 50, 54</td>
<td>damage awards for, 123</td>
</tr>
<tr>
<td>methodology for, 52–55</td>
<td>fee-shifting in, 123</td>
</tr>
<tr>
<td>in qualitative approach, 192–193</td>
<td>by NPE type, 108–109</td>
</tr>
<tr>
<td>standards analysis, 53</td>
<td>for software-based patents, 115–116</td>
</tr>
<tr>
<td>study design for, 52–55</td>
<td>in Korea, 147</td>
</tr>
<tr>
<td>as tax on innovation, 5</td>
<td>non-monetary remedies in, 118</td>
</tr>
<tr>
<td>types of, 4</td>
<td>for NPEs, 27–28</td>
</tr>
<tr>
<td>in U.S., 1</td>
<td>aggregate trends, 32–34</td>
</tr>
<tr>
<td>damage awards for, 114</td>
<td>cash-targeting strategies for, 39–40</td>
</tr>
<tr>
<td>patent law and regulation, in U.S.</td>
<td>costs to targeted firms, 43–44</td>
</tr>
<tr>
<td>bottom-feeder patent trolls under, 87–88</td>
<td>cross-country evidence for, 33–34</td>
</tr>
<tr>
<td>constitutional limits of, 85, 91–96</td>
<td>damages from, 14–16</td>
</tr>
<tr>
<td>under First Amendment, 92, 94–95</td>
<td>forum shopping for, 36–38</td>
</tr>
<tr>
<td>under Supremacy Clause, 92</td>
<td>innovation reduction as result of, 31–32,</td>
</tr>
<tr>
<td>demand letter regulations, 86</td>
<td>42–43</td>
</tr>
<tr>
<td>at federal level, 96–91</td>
<td>large sample evidence for, 31–41</td>
</tr>
<tr>
<td>at state level, 58–90</td>
<td>outcomes with SEPs, 61–62, 68, 71</td>
</tr>
<tr>
<td>under TROL Act, 91, 99–101</td>
<td>patent quality and, 32, 34–41</td>
</tr>
<tr>
<td>federal protections</td>
<td>PE litigation compared to, 39–41</td>
</tr>
<tr>
<td>demand letter regulations, 90–91</td>
<td>plaintiff classification in, 32–33</td>
</tr>
<tr>
<td>state cooperation and, 97–101</td>
<td>survey evidence for, 29–31</td>
</tr>
<tr>
<td>FTC and, 90–91</td>
<td>transfers to inventors and, 44–46</td>
</tr>
<tr>
<td>future applications of, 96–101</td>
<td>PAEs and, 27</td>
</tr>
<tr>
<td>immunity doctrine for, 86, 92–96</td>
<td>PEs and</td>
</tr>
<tr>
<td>Federal Circuit Court development of,</td>
<td>costs of, 21</td>
</tr>
<tr>
<td>92–94, 99</td>
<td>damages awards, 14–16</td>
</tr>
<tr>
<td>under First Amendment, 92, 94–95</td>
<td>NPE litigation compared to, 39–41</td>
</tr>
<tr>
<td>as matter of preemption, 92</td>
<td>Qualcomm case, 144–145</td>
</tr>
<tr>
<td>MPJH and, 93–94</td>
<td>reverse payment in, 137</td>
</tr>
<tr>
<td>re-assessment of, 94–97</td>
<td>for SEPs, litigation outcomes with NPEs,</td>
</tr>
<tr>
<td>under Supremacy Clause, 92</td>
<td>61–62, 68, 71</td>
</tr>
<tr>
<td>under PATENT Act, 91</td>
<td>in U.K., 105</td>
</tr>
<tr>
<td>for software-based patents, 116</td>
<td>in U.S., 110</td>
</tr>
<tr>
<td>under state statutes, 88–90</td>
<td>patent privateering. See also hybrid</td>
</tr>
<tr>
<td>federal cooperation and, 97–101</td>
<td>PAEs</td>
</tr>
<tr>
<td>under TROL Act, 91, 99–101</td>
<td>as consumer welfare reducing tool, 52</td>
</tr>
<tr>
<td>uniformity of, benefits of, 98</td>
<td>defined, 72</td>
</tr>
<tr>
<td>patent litigation. See also Germany, patent</td>
<td>in Korea, 146–147</td>
</tr>
<tr>
<td>litigation in; patent law and regulation,</td>
<td>MOSAID, 76–77</td>
</tr>
<tr>
<td>in U.S.; United Kingdom, patent</td>
<td>Rockstar, 51, 76</td>
</tr>
<tr>
<td>litigation in; United States, patent</td>
<td>patent quality, 30</td>
</tr>
<tr>
<td>litigation in</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NPE litigation and, 32, 34–41</td>
</tr>
<tr>
<td></td>
<td>USTPO and, 1–2</td>
</tr>
<tr>
<td></td>
<td>patent systems</td>
</tr>
</tbody>
</table>
Index 205

patent trolls and, aggregation of patents by, 18–21
PEs and, aggregation of patents by, 18–21
weakness of, 5
patent trolls. See also non-practicing entities; patent assertion entities
acquisition and aggregation of patents by, 18–21
assertion tactics of, 21–22
bottom-feeder, 11, 21–22, 25, 55
in China, 152–153
costs of, 12–16
benefits in comparison to, 22–23
as excessive, 10
myths about, 13–14
PE costs compared to, 14–16
defined, 9
injunctions against, 24
in IT industry, 9, 24
long term assessment of, 23–25
PEs and, 9–11
aggregation of patents by, 18–21
assertion tactics of, 21–22
bartering and, 12
benefits in comparison to costs, 22–23
costs of, 14–16
cross-licensing and, 13
injunctions for, 15
IT industry and, 16–18
litigation costs of, 21
patent damages for, 14–16
royalties and, 16–18
types of, 11
patented drugs, 138
PEs. See practicing entities
picture archival and communications systems
(PACS), 42–43
practicing entities (PEs), 9–11
aggregation of patents by, 18–21
assertion tactics of, 21–22
bartering and, 12
costs of, 14–16
benefits in comparison to, 22–23
cross-licensing and, 13
injunctions for, 15
IT industry and, 16
patent damages for, 14–16
patent litigation and
costs of, 21
damages awards, 14–16
NPE litigation compared to, 39–41
royalties and, 16
stacking of, 17–18
predatory pricing models, PAEs and, 2
price-fixing, 189
privateering. See patent privateering
privateering PAEs, 184–185
property law, FRAND royalty commitments and, 80–81
Protecting American Talent and Entrepreneurship (PATENT) Act (U.S.), 91
publicly-traded NPEs, 45
Qualcomm case, in Korea, 144–145
raising rivals cost (RRC) theory, 75, 177, 183
Rembrandt, 52
rent seeking, PAEs and, 5
reverse payment, defined, 137
risk asymmetry, of PAEs, 3
Rockstar, 51
patent privateering and, 76
Roppo v. Hinode, 169
royalties
FRAND under antitrust law, 81–82
contract law and, 80–81
in hybrid PAE claims, 78–79
in Korea, 141–142
property law and, 80–81
SEPs and, 50, 54
for SSOs, 50, 54
under Korean IPR guidelines, 140–141
PEs and, 16
RRC theory. See raising rivals cost theory
SEPs. See standards-essential patents
Shapiro, Carl, 182
signaling theory, in predatory pricing models, 2
software-based patents
defined, 116
in Europe, 115–116
in U.S., 116
standard setting organizations (SSOs)
hybrid PAEs and, 81
SEPs and, 50, 64–65
FRAND royalties for, 50, 54, 194
standards-essential patents (SEPs)
in Korea, 141–142
NPEs and
limitations of studies on, 63–64

© in this web service Cambridge University Press www.cambridge.org
Index

standards-essential patents (SEPs) (cont.)
litigation outcomes, 61–62, 68, 71
long-term implications of, 64–65
methodology for, 52–55
plaintiff characteristics, 58–61, 69–70
study design for, 52–55, 63–64
PAEs and, 50–51
assertion landscape, 56–58
FRAND royalties, 50, 54
limitations of, 63–64
litigation outcomes, 61–62, 68, 71
long-term implications of, 64–65
methodology for, 52–55
plaintiff characteristics, 58–61, 69–70
in qualitative approach to, 192–193
standards analysis, 53
study design for, 52–55, 63–64
patent litigation and, with NPEs, 61–62
SSOs and, 50, 64–65
FRAND royalties for, 50, 54, 104
Supremacy Clause, U.S. Constitution, 92
Supreme Court, U.S., 123
Taiwan
hybrid PAE claims in, 78–82
Nokia v. TFTC, 178–185
decision appeals, 180–181
legal issues in, 181–182
privateering PAEs and, 184–185
problems with decision, 186–187
TFTC decision, 179–180
Taiwan Fair Trade Commission (TFTC),
177–178, 195
Nokia v. TFTC decision, 179–180
appeals process, 180–181
legal issues in, 181–182
Targeting Rogue and Opaque Letters (TROL) Act (U.S.), 91, 99–101
TFEU. See Treaty on the Functioning of the European Union
TFTC. See Taiwan Fair Trade Commission
third-party patents, 141–142
Treaty on the Functioning of the European Union (TFEU), 168
TROL Act. See Targeting Rogue and Opaque Letters Act
UCPA. See Unfair Competition Prevention Act
U.K. See United Kingdom
Unfair Competition Prevention Act (UCPA) (Japan), 163
false announcement provisions,
171–173
Imation v. One Blue, 172–173
unitary patent system, 117, 124
United Kingdom (U.K.)
NPEs in, 107–110
case settlement rates, 114
by case type, 112
costs of, 116–117, 123
damage awards for, 117–118
IPCs and, 110
IPEC and, 105–106
non-monetary remedies and, 118
PAEs and, 110–112
U.S. standards for, 114
win rates for, 110, 114
United States (U.S.). See also patent law and regulation, in U.S.
antitrust law in, 77–78
hybrid PAE claims in, 77–78, 82–83
PAEs in, 1
damage awards for, 114, 117–118
patent litigation in, 110, 119–122
costs of, 116–117, 147
damage awards for, 114, 117–118
injunctions in, 118
invalidation of patents and, 118
Supreme Court and, 123
software-based patents in, 116
USTPO, patent quality and, 1–2
206

© in this web service Cambridge University Press
www.cambridge.org